SAVA News and Press, Cassava Sciences Inc. From 06/04/24

2024-06-04 05:07:02 ET Summary Cassava Sciences is advancing simufilam, a Phase 3 drug for Alzheimer's, amid scrutiny over data integrity and trial conduct. Despite operational progress, significant concerns about simufilam's efficacy and the validity of clinical data persist. ...

2024-05-10 16:48:23 ET More on Cassava Sciences Cassava Sciences: New Year, Same Game Of Smoke And Mirrors Cassava Sciences: Where Did All The Mild Alzheimer's Disease Patients Go? Cassava Sciences GAAP EPS of -$0.43 beats by $0.03 Cassava Sciences raises ove...

2024-05-10 16:07:27 ET More on Cassava Sciences Cassava Sciences: New Year, Same Game Of Smoke And Mirrors Cassava Sciences: Where Did All The Mild Alzheimer's Disease Patients Go? Cassava Sciences raises over $125M from warrant distribution Cassava Sciences ...

$126.3 Million In Total Gross Proceeds from Warrant Distribution. Over 1,900 Patients with Alzheimer’s Disease Are Randomized in Phase 3 Trials of Simufilam. Over 735 Patients Have Completed a Phase 3 Trial of Simufilam. AUSTIN, Texas, May 10, 2024 (GLOBE NE...

2024-05-09 20:43:22 ET Summary Recent results suggest that buntanetap, along with other treatments, does not significantly improve the condition of moderate Alzheimer's disease patients. Many current drug candidates for Alzheimer's disease work too far upstream in the disease proc...

2024-05-08 16:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-08 13:20:25 ET More on Cassava Sciences Cassava Sciences: New Year, Same Game Of Smoke And Mirrors Cassava Sciences: Where Did All The Mild Alzheimer's Disease Patients Go? Cassava Sciences And Alzheimer's Disease: Opaque Clarity Cassava Sciences agai...

AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company”), a biotechnology company focused on Alzheimer’s disease, today announced total gross proceeds of over $125 million from cash-exercises of warrants that were previously distri...

2024-05-07 10:47:03 ET ProShares UltraPro Short QQQ (SQQQ) SQQQ is trading DOWN for the last 4 days, and it at trading at $10.69 with volume of 30,905,666 and a one day change of $-0.01 (-0.09%). ProShares UltraPro Short QQQ has a 52-week low of 10.05 and a 52-week high of $29.28. T...

PRA Group Inc. (PRAA) is expected to report $-0.15 for Q1 2024 Bowman Consulting Group Ltd. (BWMN) is expected to report $-0.04 for Q1 2024 Noble Corporation plc A (NE) is expected to report $0.56 for Q1 2024 Velo3D Inc. (VLD) is expected to report for Q3 2024 Axon Enterprise Inc....